Medicare to save $6B in 2026 from the first ever Part D drug pricing negotiations

Contributing sentiments towards policy:

57% : Medicare can target small molecule drugs, typically pills, nine years after entering the market, and large molecule drugs, delivered via IV, 13 years after hitting the market.
56% : The year-long negotiation process will yield savings of $6 billion in 2026, off of net prices paid by Medicare, according to U.S. Health Secretary Xavier Becerra.
55% : In addition, Medicare will soon start to negotiate for Part B, or prescription drugs that are administered in hospital environments or in doctor's offices.
53% : The price list marks the first time in U.S. history that Medicare has negotiated the prices of drugs directly with the manufacturers.
50% : The Centers for Medicare and Medicaid Services (CMS) has noted that it is particularly interested in drugs that have no generic or biosimilar competition.
43% : The Crohn's disease treatment brought in $9.7 billion for 2022, and Medicare claims it costs the government $2.3 billion per year for Part D. Other drugs contribute less to the top line for companies, so a lower price in the long term will not have significant impact.

*Our bias meter rating uses data science including sentiment analysis, machine learning and our proprietary algorithm for determining biases in news articles. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral. The rating is an independent analysis and is not affiliated nor sponsored by the news source or any other organization.